Background
Materials and methods
Search strategy
Criteria for inclusion and exclusion
Data collection
Statistical analysis
Results
Characteristics of studies
References | Year | Country | Histological type | Case (n) | HIF-1α + (n) | HIF-1α + (%) | Survival | Follow-up (months) | NOS score | Quality |
---|---|---|---|---|---|---|---|---|---|---|
Bao [21] | 2013 | China | Osteosarcoma | 108 | 62 | 57 | OS | 60 | 4 | Low |
Boeuf [22] | 2010 | Germany | Chondrosarcoma | 32 | 14 | 44 | DFS | 100 | 4 | Low |
Chen [23] | 2008 | China | Osteosarcoma | 25 | 17 | 68 | NR | NR | 3 | Low |
Chen [24] | 2010 | China | Chondrosarcoma | 34 | 20 | 59 | OS | 100 | 4 | Low |
Chen [25] | 2012 | China | Osteosarcoma | 49 | 27 | 55 | DFS | 100 | 6 | High |
Geng [26] | 2008 | China | Osteosarcoma | 59 | 23 | 39 | OS | 50 | 6 | High |
Guan [27] | 2014 | China | Osteosarcoma | 52 | 46 | 88 | NR | NR | 3 | Low |
Guo [28] | 2014 | China | Osteosarcoma | 98 | 78 | 80 | OS | 120 | 4 | Low |
Hu [29] | 2009 | China | Osteosarcoma | 35 | 23 | 66 | NR | NR | 3 | Low |
Hu [30] | 2015 | China | Osteosarcoma | 50 | 29 | 58 | DFS | 50 | 4 | Low |
Kubo [31] | 2008 | Japan | Chondrosarcoma | 20 | 8 | 40 | DFS | 120 | 4 | Low |
Li [32] | 2012 | China | Osteosarcoma | 102 | 47 | 46 | NR | NR | 3 | Low |
Li [33] | 2015 | China | Osteosarcoma | 28 | 15 | 54 | NR | NR | 4 | Low |
Lian [34] | 2013 | China | Osteosarcoma | 35 | 12 | 34 | NR | NR | 3 | Low |
Luo [35] | 2009 | China | GCTB | 51 | 32 | 63 | NR | NR | 4 | Low |
Ma [36] | 2014 | China | GCTB | 80 | 40 | 50 | NR | NR | 4 | Low |
Mao [37] | 2007 | China | Osteosarcoma | 64 | 37 | 58 | NR | NR | 4 | Low |
Mizobuchi [38] | 2008 | USA | Osteosarcoma | 48 | 18 | 38 | NR | NR | 3 | Low |
Naggar [39] | 2012 | Canada | Osteosarcoma | 25 | 13 | 52 | NR | NR | 3 | Low |
Qian [40] | 2007 | China | Osteosarcoma | 25 | 14 | 56 | NR | NR | 4 | Low |
Wang [41] | 2004 | China | Osteosarcoma | 46 | 16 | 35 | OS | 70 | 5 | High |
Wang [42] | 2017 | China | Osteosarcoma | 103 | 57 | 55 | OS | 120 | 7 | High |
Wu [43] | 2010 | China | Osteosarcoma | 36 | 15 | 42 | NR | NR | 3 | Low |
Yang [44] | 2007 | China | Osteosarcoma | 39 | 31 | 79 | OS/DFS | 100 | 6 | High |
Yin [45] | 2010 | China | Osteosarcoma | 36 | 22 | 61 | OS | 36 | 5 | High |
Zeng [46] | 2010 | China | Osteosarcoma | 45 | 25 | 56 | OS | 60 | 6 | High |
Zhao [47] | 2015 | China | Osteosarcoma | 88 | 50 | 57 | OS | 107 | 7 | High |
Zheng [48] | 2009 | China | Osteosarcoma | 30 | 15 | 50 | NR | NR | 4 | Low |
Correlation between HIF-1α and the clinicopathological features
Clinicopathological features | Number of studies | Number of case (n) | Number of HIF-1α + (n) | Pooled data | Test for heterogeneity | ||||
---|---|---|---|---|---|---|---|---|---|
RR | 95% CI | P value |
χ
2
| P value | I2 (%) | ||||
Gender (male vs. female) | 13 | 832 | 500 | 0.93 | 0.83–1.04 | 0.179 | 12.97 | 0.371 | 7.5 |
Age (year) (≤ 20 vs. > 20) | 6 | 481 | 303 | 1.19 | 1.00–1.41 | 0.055 | 8.72 | 0.121 | 42.7 |
Size (cm) (≥ 5.0 vs. < 5) | 7 | 378 | 222 | 1.19 | 0.99–1.44 | 0.069 | 6.86 | 0.334 | 12.6 |
Differentiation (poor vs. well/moderate) | 8 | 272 | 174 | 1.56 | 1.00–2.43 | 0.049 | 28.33 | < 0.001 | 75.3 |
Clinical stage (II/III vs. I) | 6 | 396 | 207 | 1.75 | 1.25–2.45 | 0.001 | 8.89 | 0.113 | 43.8 |
Metastasis (yes vs. no) | 14 | 870 | 503 | 1.78 | 1.58–2.00 | < 0.001 | 24.91 | 0.024 | 47.8 |
Association between HIF-1α and prognosis in patients with bone tumor
Subgroup analyses
Subgroups | Number of studies | Case (n) | HIF-1α + (n) | HIF-1α + (%) | Pooled data | Test for heterogeneity | |||
---|---|---|---|---|---|---|---|---|---|
HR | 95% CI | P value | P value | I2 (%) | |||||
Histological type | |||||||||
Osteosarcoma | 9 | 622 | 364 | 59 | 2.60 | 2.09–3.24 | < 0.001 | 0.684 | 0 |
Chondrosarcoma | 1 | 34 | 20 | 59 | 2.83 | 1.11–7.22 | 0.030 | NA | NA |
Case (n) | |||||||||
< 50 | 5 | 200 | 114 | 57 | 2.40 | 1.84–3.12 | < 0.001 | 0.770 | 0 |
≥ 50 | 5 | 456 | 270 | 59 | 3.07 | 2.14–4.40 | < 0.001 | 0.451 | 0 |
Follow-up (months) | |||||||||
< 100 | 5 | 294 | 184 | 50 | 2.55 | 1.97–3.30 | < 0.001 | 0.578 | 0 |
≥ 100 | 5 | 362 | 236 | 65 | 2.76 | 1.88–4.04 | < 0.001 | 0.608 | 0 |
Quality | |||||||||
High | 7 | 416 | 224 | 54 | 2.70 | 2.13–3.43 | < 0.001 | 0.581 | 0 |
Low | 3 | 240 | 160 | 67 | 2.30 | 1.44–3.68 | < 0.001 | 0.732 | 0 |
Subgroups | Number of studies | Case (n) | HIF-1α + (n) | HIF-1α + (%) | Pooled data | Test for heterogeneity | |||
---|---|---|---|---|---|---|---|---|---|
HR | 95% CI | P value | P value | I2 (%) | |||||
Region | |||||||||
Non-Asian | 2 | 52 | 22 | 42 | 1.87 | 1.15–3.04 | 0.011 | 0.233 | 29.7 |
Asian | 3 | 138 | 87 | 63 | 2.21 | 1.30–3.78 | 0.004 | 0.454 | 0 |
Histological type | |||||||||
Osteosarcoma | 3 | 138 | 87 | 63 | 2.21 | 1.30–3.78 | 0.004 | 0.454 | 0 |
Chondrosarcoma | 2 | 52 | 22 | 42 | 1.87 | 1.15–3.04 | 0.011 | 0.233 | 29.7 |
Case (n) | |||||||||
< 40 | 3 | 91 | 53 | 58 | 1.93 | 1.23–3.02 | 0.004 | 0.467 | 0 |
≥ 40 | 2 | 99 | 56 | 57 | 2.19 | 1.21–3.97 | 0.010 | 0.210 | 36.4 |
Follow-up (months) | |||||||||
< 100 | 1 | 50 | 29 | 58 | 1.90 | 1.01–3.58 | 0.047 | NA | NA |
≥ 100 | 4 | 140 | 80 | 57 | 2.08 | 1.34–3.21 | 0.001 | 0.368 | 5 |
Quality | |||||||||
High | 2 | 88 | 58 | 66 | 3.22 | 1.19–8.68 | 0.021 | 0.368 | 0 |
Low | 3 | 102 | 51 | 50 | 1.88 | 1.28–2.77 | 0.001 | 0.491 | 0 |